CD34 and plasma cell myeloma: It is interesting that the long-term overall survival of the multiple myeloma patients allografted with more than 1 x 106 CD34 +ve viable cells / Kg was better (80% at 80 months) than those autografted with less than 1 x 106 CD34 +ve viable cells / Kg (67% at 76 months); the differences however are not statistically significant according to the log-rank chi square method most likely as a result of the low number of patients included in the study, see table 1 and figure 1.